CN102372673A - Blonanserin crystallization and preparation method thereof - Google Patents
Blonanserin crystallization and preparation method thereof Download PDFInfo
- Publication number
- CN102372673A CN102372673A CN2010102643411A CN201010264341A CN102372673A CN 102372673 A CN102372673 A CN 102372673A CN 2010102643411 A CN2010102643411 A CN 2010102643411A CN 201010264341 A CN201010264341 A CN 201010264341A CN 102372673 A CN102372673 A CN 102372673A
- Authority
- CN
- China
- Prior art keywords
- blonanserin
- crystallization
- solvent
- ethanol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 229950002871 blonanserin Drugs 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000002425 crystallisation Methods 0.000 title claims abstract description 17
- 230000008025 crystallization Effects 0.000 title claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 229940043232 butyl acetate Drugs 0.000 claims description 5
- 230000007704 transition Effects 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 3
- 239000008109 sodium starch glycolate Substances 0.000 claims description 3
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000001953 recrystallisation Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 229940035429 isobutyl alcohol Drugs 0.000 abstract 1
- 239000003208 petroleum Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000009413 insulation Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- PAADHXDWLFDAON-UHFFFAOYSA-N cycloocta[b]pyridine Chemical compound C1=CC=CC=CC2=CC=CN=C21 PAADHXDWLFDAON-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- -1 hydrogen cycloocta-[b] pyridines Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5, 6, 7, 8, 9, 10-hexahydrocycloocta [b] pyridine (Blonanserin) crystallization and a preparation method thereof. The method includes the following steps: 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5, 6, 7, 8, 9, 10-hexahydrocycloocta [b] pyridine (Blonanserin) is heated to be dissolved in the mixture of ethanol, n-butyl alcohol, tertiary butanol, isobutyl alcohol, petroleum ether, butyl acetate, ethanol and isopropanol, and the Blonanserin crystallization is then obtained by way of recrystallization. The Blonanserin crystallization prepared by the method is safe, low in toxicity and stable for light, wet and heat, and is convenient to produce and store. Meanwhile, the invention also provides a drug combination containing the Blonanserin crystallization as an antipsychotic drug.
Description
Technical field
The invention belongs to technical field of medicine synthesis, relate to a kind of 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine (blonanserin, Blonanserin) crystalline preparing methods.
Background technology
Blonanserin has a chemical structure of innovation fully as the anti-schizophrenia medicine of a new generation, the clinical psychosis that is used for, and tool Dopamine HCL and 5-hydroxytryptamine receptor dual antagonist are active, and the untoward reaction rate is low than other positive drug.Clinical study shows that these article all have quite or better therapeutic with respect to haloperidol that has gone on the market and risperidone, lower adverse reaction rate.
Blonanserin (Blonanserin), chemistry 2-(4-ethyl-1-piperazinyl) by name-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridines, chemical structural formula:
Summary of the invention
The object of the present invention is to provide a kind of blonanserin 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine crystallizations, the clinical psychosis that is used for is treated.
Another object of the present invention is to provide the blonanserin crystalline preparation method that is fit to suitability for industrialized production.
A further object of the present invention is to provide and contains blonanserin crystalline pharmaceutical composition.For realizing above-mentioned purpose, the present invention provided following technical scheme:
A kind of blonanserin crystallization is characterized in that using the Cu-Ka radiation, to spend X-ray powder diffraction spectrum that 2 θ represent 7.78 ± 0.2,9.92 ± 0.2,10.70 ± 0.2,12.00 ± 0.2; 13.04 ± 0.2,15.68 ± 0.2,16.08 ± 0.2,17.52 ± 0.2,18.04 ± 0.2,18.50 ± 0.2; 18.74 ± 0.2,19.18 ± 0.2,19.72 ± 0.2,20.10 ± 0.2,20.56 ± 0.2; 21.00 ± 0.2,22.70 ± 0.2,24.68 ± 0.2,25.28 ± 0.2,25.96 ± 0.2; 27.28 ± 0.2,25.92 ± 0.2,30.74 ± 0.2,31.74 ± 0.2,36.42 ± 0.2 have characteristic peak; Infrared absorption pattern is at 2919 ± 5cm
1, 2822 ± 5cm
1, 1585 ± 5cm
1, 1507 ± 5cm
-1There is absorption peak at the place; Its DSC endothermic transition is at 124 ℃.
Blonanserin crystallization of the present invention, its X-ray powder diffraction 2 θ positions 19.18 ± 0.2 place's diffraction intensities are 100%.
The invention discloses blonanserin crystalline preparation method, it is characterized in that: with the blonanserin dissolving crude product in organic solvent, after treating to dissolve fully; Slowly be cooled to 23-27 ℃ again, be incubated 90-100 minute, reduce to-9 to-5 ℃; Be incubated 3～5 hours; Filter, heat drying obtains same blonanserin crystal to constant weight; Wherein said organic solvent comprises: (1) ethanol, propyl carbinol, the trimethyl carbinol, isopropylcarbinol, sherwood oil or butylacetate single solvent;
(2) mixed solvent of ethanol and Virahol.
Wherein the mixed solvent consumption of the single solvent of (1) or (2) is 1.5～30 times of ml/g of blonanserin bullion.Preferably the mixed solvent consumption of the single solvent of (1) or (2) be the blonanserin bullion 5～10 times of ml/g, particularly ethanol and the ratio of weight and number of isopropyl alcohol mixed solvent be 0.5: 1～2: 1.
Of the present invention being dissolved in the organic solvent refers to: 40 ℃ of heating for dissolving to the reflux temperature of solvent.
The inventor is through a large amount of experiments; Selected multiple safety, low toxicity, acceptable for pharmaceutical solvent, all can obtain blonanserin crystal formation of the present invention through recrystallization method as adopting ethanol, propyl carbinol, the trimethyl carbinol, isopropylcarbinol, sherwood oil, butylacetate single solvent.Further adopt the mixed solvent of ethanol and Virahol, its ratio is 0.5: 1～2: 1.Also can obtain blonanserin crystal formation of the present invention through recrystallization method.
The process of recrystallization comprises: with 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7; 8,9,10-six hydrogen cycloocta-[b] pyridine (blonanserins; Blonanserin) in the mixed solvent of ethanol, propyl carbinol, the trimethyl carbinol, isopropylcarbinol, sherwood oil or butylacetate single solvent or ethanol and Virahol, heat, after treating to dissolve fully, slowly be cooled to 25 ± 2 ℃ again; Be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 3～5 hours, filter; Heat drying obtains the crystal formation with a kind of blonanserin to constant weight.
Blonanserin (Blonanserin) crystallization of the present invention's preparation has following characteristic:
1.X-ray powder diffraction:
Instrument: Japanese D/max2500 type X-ray diffractometer of science;
Target: 2 θ sweep limit: 0-50 ° of Cu-K a radiation
Step angle: 0.04 ℃
Computing time: 0.5 second
Pipe is pressed: 40KV
Pipe stream: 100mA
Sweep velocity: 8 ℃/min
Filter disc: graphite monochromator
| 2θ | Spacing (d value) | I/I 0 |
| 7.78 | 11.35 | 13 |
| 9.28 | 9.52 | 3 |
| 9.92 | 8.91 | 5 |
| 10.70 | 8.26 | 5 |
| 12.00 | 7.37 | 10 |
| 13.04 | 6.78 | 5 |
| 15.68 | 5.65 | 50 |
| 16.08 | 5.51 | 20 |
| 17.52 | 5.06 | 13 |
| 18.04 | 4.91 | 13 |
| 18.50 | 4.79 | 17 |
| 18.74 | 4.73 | 19 |
| 19.18 | 4.62 | 100 |
| 19.72 | 4.50 | 16 |
| 20.10 | 4.41 | 23 |
| 20.56 | 4.31 | 7 |
| 21.00 | 4.23 | 8 |
| 21.54 | 4.12 | 6 |
| 21.90 | 4.05 | 7 |
| 22.70 | 3.91 | 8 |
| 23.66 | 3.76 | 6 |
| 24.68 | 3.60 | 25 |
| 25.28 | 3.52 | 6 |
| 25.96 | 3.43 | 20 |
| 27.28 | 3.27 | 21 |
| 29.52 | 3.02 | 9 |
| 30.74 | 2.91 | 9 |
| 31.74 | 2.82 | 6 |
| 32.66 | 2.74 | 5 |
| 33.92 | 2.64 | 4 |
| 36.42 | 2.46 | 8 |
| 37.98 | 2.37 | 4 |
| 40.64 | 2.22 | 4 |
| 44.32 | 2.04 | 5 |
2. dsc (DSC):
Instrument: Japanese standard type TG-DTA analyser of science
TR: room temperature～400 ℃
Heat-up rate: 10 ℃/minute
Its endothermic transition of blonanserin is at about 124 ℃.
3. ir spectra (IR):
Instrument: PE-983G IR
Specimen preparation: KBr compressing tablet
The ir spectra wave number of blonanserin (pressing potassium bromide troche) is (cm
-1) be: at about 2919 ± 5cm
-1, 2822 ± 5cm
-1, 1585 ± 5cm
-1, 1507 ± 5cm
-1Characteristic spectrum belt is arranged.
4. fusing point:
Instrument: YTR-3 type fusing point appearance (Precision Instrument Factory, Tianjin Univ.)
The blonanserin crystalline melting point is 124～125 ℃.
Blonanserin physico-chemical property and pharmacodynamic study thereof
One, the stability of blonanserin crystal habit
(1) gets the blonanserin crystallization in weighing bottle, respectively at 60 ℃, 4500 ± 500LX illumination and 92.5% relative humidity held, in sampling in 5 days, 10 days, high effective liquid chromatography for measuring related substance, result such as table 1
Table 1 blonanserin influence factor is measured the result
Conclusion: blonanserin was 60 ℃, 4500 ± 500LX illumination and 92.5% relative humidity held 5,10 days, and related substance is not all seen obvious change, and powdery diffractometry is not seen variation.
(2) slope of repose determination test
For confirming the flowability of this crystal formation compressing tablet powder, measured the slope of repose of three lot sample article powder.Use the 20g powder, in the triangular funne of packing into, powder is fallen naturally, form a conical pile, with its base diameter of vernier caliper measurement, it is high to measure heap with vernier height gauge, calculates its slope of repose, and the result sees the following form 2:
The result is measured at table 2 blonanserin slope of repose
Spend good fluidity by visible these article tablet powder slope of repose of result in the table less than 40.
(3) blonanserin dissolution of crystals degree
Table 3 blonanserin dissolution of crystals degree is measured the result
The part omitted of these article 0.1M hydrochloric acid soln is dissolved, and slightly soluble in methyl alcohol, ethanol is insoluble in water.
Two, the pharmacokinetics behind the oral blonanserin crystal formation of the rat raw material
The invention provides psychotolytic treat-ment, this method be to the patient give with pharmacology on the blonanserin of crystal habit of significant quantity.Pharmacokinetic behind the oral blonanserin crystal formation of the rat raw material shows that blonanserin absorbs at the all-digestive tract except that stomach, and its specific absorption is 80～98%.Behind the blonanserin to rat single oral 10mg/kg, 52% by being drained in bile, about 40% (dosage about 1/5) is absorbed again, is the liver sausage circulation.Visible from medicine for parameter, the Stability Analysis of Structures of crystal formation, absorption in animal body, elimination basically identical.Pharmaceutical composition provided by the invention contains the blonanserin and the pharmaceutically acceptable carrier of crystal habit.
The blonanserin of crystal habit of the present invention is suitable for oral Preparation, comprises fast-release tablet, chewable tablet, dispersible tablet, effervescent tablet, slow releasing tablet, controlled release tablet, enteric coated tablet etc. like tablet; Capsule comprises hard capsule, soft capsule, slow releasing capsule, controlled release capsule, enteric coated capsule etc.; Granule comprises mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules, controlled release granule etc.; Oral solution; Oral suspensions; Syrup or the like.Preparation is during oral solid formulation, can blonanserin crystallization and suitable pharmaceutical excipient processed the particle pack or pack gelatine capsule or compacting in flakes.
Acceptable carrier comprises one or more pharmaceutical excipients on the pharmacology, and for example tackiness agent, thinner, disintegrating agent, sanitas, dispersion agent, glidant and lubricant or the like are the auxiliary material commonly used in the preparation.The peroral administration optimised form of this compsn is a tablet.
The positively effect that the blonanserin of crystal habit of the present invention is compared with prior art had is:
(1) 2-provided by the invention (4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7; 8,9,10-six hydrogen cycloocta-[b] pyridine (blonanserins; Blonanserin) preparation of crystal formation, the solvent toxicity of employing is little, the production safe preparation process; Resulting quality product is high, can residual more toxic substance, meet the required standard of SFDA.
(2) the prepared blonanserin crystal of the present invention because intramolecule is ordered arrangement, thereby has increased stability effectively; Also increase simultaneously the solvability of medicine, promoted the absorption of medicine, improved bioavailability.
(3) the prepared blonanserin crystal of the present invention also has good mobile and good preparation performance.To light, wet, thermally-stabilised, be fit to long storage, be more suitable for industrialized production.
Description of drawings
Fig. 1 a, Fig. 1 b are blonanserin (Blonanserin) crystalline X-ray powder diffraction collection of illustrative plates.
Fig. 2 is blonanserin (Blonanserin) crystalline infared spectrum.
Fig. 3 is blonanserin (Blonanserin) crystalline DSC endothermic transition collection of illustrative plates.
Fig. 4 is the mass spectrum (Ms) of blonanserin (Blonanserin).
Fig. 5 be blonanserin (Blonanserin) proton nmr spectra (
1H-NMR).
Specific embodiment
Below in conjunction with embodiment the present invention is done further explanation, make this area professional and technical personnel better understand the present invention.It is indicative that embodiment is merely, and means that never it limits scope of the present invention by any way.
Used blonanserin (Blonanserin) among the present invention, i.e. 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridines are that the method that provides according to document EP 385273 is synthetic.The synthetic blonanserin is through mass spectrum (Ms), proton nmr spectra (
1H-NMR) etc. conclusive evidence proves that chemical structure is correct, sees Fig. 4, Fig. 5.
Preparation embodiment
Blonanserin bullion 1g is added ethanol 10ml, be heated to backflow, after treating to dissolve fully, slowly be cooled to 25 ± 2 ℃ again; Be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 5 hours, filter; Heat drying obtains blonanserin crystal form samples 0.85g of the present invention to constant weight, and HPLC measures 99.8%.
Blonanserin bullion 1g is added propyl carbinol 15ml, be heated to backflow, after treating to dissolve fully; Slowly be cooled to 25 ± 2 ℃ again, be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 3 hours; Filter; Heat drying obtains blonanserin crystal form samples 0.8g of the present invention to constant weight, and HPLC measures 99.6%.
Blonanserin bullion 1g is added trimethyl carbinol 20ml, be heated to backflow, after treating to dissolve fully; Slowly be cooled to 25 ± 2 ℃ again, be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 3 hours; Filter; Heat drying obtains blonanserin crystal form samples 0.75g of the present invention to constant weight, and HPLC measures 99.7%.
Blonanserin bullion 1g is added isopropylcarbinol 8ml, be heated to backflow, after treating to dissolve fully, slowly be cooled to 25 ± 2 ℃ again; Be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 5 hours, filter; Heat drying obtains blonanserin crystal form samples 0.8g of the present invention to constant weight, and HPLC measures 99.8%.
Blonanserin bullion 1g is added sherwood oil 5ml, be heated to backflow, after treating to dissolve fully; Slowly be cooled to 25 ± 2 ℃ again, be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 3 hours; Filter; Heat drying obtains blonanserin crystal form samples 0.86g of the present invention to constant weight, and HPLC measures 99.5%.
Blonanserin bullion 1g is added butylacetate 25ml, be heated to 40 ℃ of dissolvings after, slowly be cooled to 25 ± 2 ℃ again; Be incubated 90 minutes, reduce to-7 ± 2 ℃ of insulations 5 hours, filter; Heat drying obtains blonanserin crystal form samples 0.7g of the present invention to constant weight, and HPLC measures 99.7%.
Blonanserin bullion 1g is added ethanol 5ml and Virahol 5ml; After being heated to dissolving fully, slowly be cooled to 25 ± 2 ℃ again, reduce to-7 ± 2 ℃ again and leave standstill insulation 5 hours; Filter; Heat drying is loss of weight extremely no longer, obtains blonanserin crystal form samples 0.85g of the present invention, and HPLC measures 99.7%.
Blonanserin bullion 1g is added ethanol 5ml and Virahol 10ml; After being heated to dissolving fully, slowly be cooled to 25 ± 2 ℃ again, reduce to-7 ± 2 ℃ again and leave standstill insulation 5 hours; Filter; Heat drying is loss of weight extremely no longer, obtains blonanserin crystal form samples 0.81g of the present invention, and HPLC measures 99.7%.
FORMULATION EXAMPLE
Blonanserin crystallization 4g, Microcrystalline Cellulose 80g, lactose 150g, sodium starch glycolate 5g, Magnesium Stearate 2g, PVPP 5g, micropowder silica gel 2g processes 1000.
Blonanserin crystallization bulk drug is ground, cross 200 mesh sieves, filter, drain, 60 ℃ of dryings, the inspection related substance promptly gets.Get Microcrystalline Cellulose, sodium starch glycolate, lactose, Magnesium Stearate, PVPP, the differential silica gel of recipe quantity and cross 100 mesh sieves; With blonanserin and the mixing of auxiliary material grinding uniformly, cross 60 mesh sieves three times with the stepwise dilution method.It is an amount of to add 60% ethanolic soln, granulates with 20 mesh sieves.Put 60 ℃ of dryings, with the whole grain of 30 mesh sieves, sampling and measuring content and related substance, stator is heavy, and compressing tablet is processed 1000.
Claims (9)
1. a blonanserin crystallization is characterized in that using the Cu-Ka radiation,
To spend X-ray powder diffraction spectrum that 2 θ represent 7.78 ± 0.2,9.92 ± 0.2,10.70 ± 0.2,12.00 ± 0.2,13.04 ± 0.2; 15.68 ± 0.2,16.08 ± 0.2,17.52 ± 0.2,18.04 ± 0.2,18.50 ± 0.2; 18.74 ± 0.2,19.18 ± 0.2,19.72 ± 0.2,20.10 ± 0.2,20.56 ± 0.2; 21.00 ± 0.2,22.70 ± 0.2,24.68 ± 0.2,25.28 ± 0.2,25.96 ± 0.2; 27.28 ± 0.2,25.92 ± 0.2,30.74 ± 0.2,31.74 ± 0.2,36.42 ± 0.2 have characteristic peak; Infrared absorption pattern is at 2919 ± 5cm
-1, 2822 ± 5cm
-1, 1585 ± 5cm
-1, 1507 ± 5cm
-1There is absorption peak at the place; Its DSC endothermic transition is at 124 ℃.
2. the described blonanserin crystallization of claim 1, its described X-ray powder diffraction 2 θ positions 19.18 ± 0.2 place's diffraction intensities are 100%.
3. one kind prepares the said blonanserin crystalline of claim 1 method, it is characterized in that: with the blonanserin dissolving crude product in organic solvent, after treating to dissolve fully; Slowly be cooled to 23-27 ℃ again, be incubated 90-100 minute, reduce to-9 to-5 ℃; Be incubated 3～5 hours; Filter, heat drying obtains same blonanserin crystal to constant weight; Wherein said organic solvent comprises: (1) ethanol, propyl carbinol, the trimethyl carbinol, isopropylcarbinol, sherwood oil or butylacetate single solvent; (2) mixed solvent of ethanol and Virahol.
4. the described preparation method of claim 3, wherein the mixed solvent consumption of the single solvent of (1) or (2) is 1.5～30 times of ml/g of blonanserin bullion.
5. the described preparation method of claim 4, wherein the mixed solvent consumption of the single solvent of (1) or (2) be the blonanserin bullion 5～10 times of ml/g.
6. each described preparation method of claim 3-6, wherein the ratio of weight and number of ethanol and isopropyl alcohol mixed solvent is 0.5: 1～2: 1.
7. the described preparation method of claim 3, wherein said being dissolved in the organic solvent refers to: 40 ℃ of heating for dissolving to the reflux temperature of solvent.
8. pharmaceutical composition, said composition contains right and requires 1 described blonanserin crystallization and pharmaceutically acceptable carrier thereof.
9. the described compsn of claim 8 is characterized in that tablet or capsule are processed in combinations such as blonanserin and Microcrystalline Cellulose, lactose, micropowder silica gel, Magnesium Stearate, PVPP, polyvidone, HPMC, sodium starch glycolate, Sodium Croscarmellose, low-substituted hydroxypropyl cellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010264341.1A CN102372673B (en) | 2010-08-27 | 2010-08-27 | Blonanserin crystallization and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010264341.1A CN102372673B (en) | 2010-08-27 | 2010-08-27 | Blonanserin crystallization and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102372673A true CN102372673A (en) | 2012-03-14 |
| CN102372673B CN102372673B (en) | 2014-04-09 |
Family
ID=45791959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010264341.1A Active CN102372673B (en) | 2010-08-27 | 2010-08-27 | Blonanserin crystallization and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102372673B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831578A (en) * | 2017-02-14 | 2017-06-13 | 北京万全德众医药生物技术有限公司 | The method of purification of antipsychotic drug blonanserin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021421A (en) * | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
| CN101747274A (en) * | 2008-12-02 | 2010-06-23 | 浙江华海药业股份有限公司 | Method for preparing crystal form A of blonanserin |
-
2010
- 2010-08-27 CN CN201010264341.1A patent/CN102372673B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021421A (en) * | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
| CN101747274A (en) * | 2008-12-02 | 2010-06-23 | 浙江华海药业股份有限公司 | Method for preparing crystal form A of blonanserin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831578A (en) * | 2017-02-14 | 2017-06-13 | 北京万全德众医药生物技术有限公司 | The method of purification of antipsychotic drug blonanserin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102372673B (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6705833B2 (en) | Co-crystal of ibrutinib and carboxylic acid | |
| JP5934204B2 (en) | Pharmaceutical composition of C-MET modulator | |
| US9309201B2 (en) | Process for preparating ivabradine hydrochloride form IV and methods of treatment of disease using ivabradine hydrochloride form IV | |
| EP3845221B1 (en) | Solid state forms of sofosbuvir | |
| JP7166292B2 (en) | Crystalline solid form of salt of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, preparation Process and usage | |
| WO2014016848A2 (en) | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof | |
| CN105777636A (en) | Salt and solvates of a tetrahydroisoquinoline derivative | |
| CN104414989A (en) | Ticagrelor pharmaceutical composition and preparation method thereof | |
| CN101691372B (en) | Citric acid alidenafil crystal form C and preparation method and application thereof | |
| KR102298597B1 (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride | |
| CN102964384A (en) | Adefovir dipivoxil gallic acid eutectic, and preparation method and composition thereof | |
| CN104926800A (en) | Crystal form of afatinib di-meleate and method for preparing crystal form | |
| CN102372673B (en) | Blonanserin crystallization and preparation method thereof | |
| JP7404361B2 (en) | Novel amorphous active pharmaceutical ingredient | |
| WO2019134455A1 (en) | Novel crystal form of acalabrutinib and preparation method and use thereof | |
| KR20160068979A (en) | Amorphous allisartan isoproxil, preparation method thereof, and pharmaceutical composition containing amorphous allisartan isoproxil | |
| CN114630668B (en) | Aprocitentan crystal form and preparation method and application thereof | |
| CN104755481A (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
| WO2019105359A1 (en) | Crystal form of acalabrutinib, preparation method therefor and application thereof | |
| EP3704124A1 (en) | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor | |
| CN114867723B (en) | Salt forms, crystal forms and pharmaceutical compositions of pyridyloxy-pyrazoles as TGF-beta R1 inhibitors | |
| JP5589097B2 (en) | Dasatinib polycrystal, preparation method thereof and drug composition | |
| CN106554377B (en) | Morphine derivatives crystal form III and its preparation method and application | |
| CN106554357B (en) | Morphine derivatives crystal form I and its preparation method and application | |
| WO2021097650A1 (en) | Cocrystal of orlistat and amino acid, and pharmaceutical composition comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |